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procedures and clinical outcomes between the two groups were analyzed using chi 
square and one-way t-tests. Costs included therapeutic management, hospitalization, 
and amputation. Outcomes included the numbers of amputations and deaths, and 
length of stay. The analysis was performed from the Singapore hospital perspective, 
using 2008 Singapore dollars. RESULTS: The LEAP group had a lower amputation 
rate (29% vs. 76%, P < 0.001), lower death rate (0.4% vs. 13.2%, P < 0.001) and 
fewer in-hospital days (17.8 days vs. 23.16 days, P = 0.048). Furthermore, implemen-
tation of the LEAP strategy generated cost savings of 2566 Singapore dollars per 
patient compared with the pre-LEAP strategy. The results were sensitive to amputation 
rates, cost per amputation, and cost per bed day. However, the LEAP is cost saving 
across all plausible variations in parameters (95% conﬁ dence interval limits for the 
reduction in amputation rates, 25% variation in costs). CONCLUSIONS: Use of 
non-randomized study data and a retrospective comparator require the results of this 
study to be interpreted with caution. However, the results suggest the LEAP strategy 
dominates standard practice for the management of patients with diabetes and CLI 
being both cost saving and more effective. 
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OBJECTIVES: The OnceMix and INITIATE studies have indicated that biphasic 
insulin aspart 30 (BIAsp 30) is more effective than insulin glargine (IGlarg) in terms 
of reductions in glycohemoglobin in type 2 diabetes patients requiring insulin initia-
tion. Our aim was to estimate the cost-effectiveness of BIAsp 30 versus IGlarg in the 
Chinese setting. METHODS: The previously published IMS Core Diabetes Model was 
used. The nephropathy, retinopathy and stroke sub-models were modiﬁ ed to incor-
porate available Chinese clinical data. Diabetes complication costs were derived from 
hospital surveys in Beijing and Chengdu. Simulated cohorts and insulin treatment 
effects were based on the OnceMix study for once-daily BIAsp 30 versus IGlarg and 
on the INITIATE study for twice-daily BIAsp 30 versus IGlarg. Life expectancy and 
direct medical costs were calculated. Projections were made over 30-year time hori-
zons, with costs and life-years discounted at 3% annually. Extensive sensitivity analy-
ses were performed, including adjustments to cardiovascular risk for Chinese ethnicity. 
RESULTS: Once-daily BIAsp 30 increased life expectancy by 0.04 years (12.37 vs. 
12.33 years) and reduced direct medical costs by Chinese Yuan (CNY) 59,710 per 
patient (CNY 229,911 vs. CNY 289,621 per patient) compared to IGlarg in the 
OnceMix-based analysis. Twice-daily BIAsp 30 increased life expectancy by 0.08 years 
(12.99 vs. 12.91 years) and reduced direct medical costs by CNY 107,349 per patient 
(CNY 303,142 vs. CNY 410,491 per patient) compared to IGlarg in the INITIATE-
based analysis. Improvements in life expectancy were driven by reduced incidences of 
most diabetes-related complications. Cost savings were attributable to lower insulin 
costs for BIAsp 30 compared to IGlarg in China. Lowering cardiovascular risk for 
Chinese ethnicity reduced the modeled clinical improvements for BIAsp 30 but 
increased treatment-related cost savings. CONCLUSIONS: BIAsp 30, either once- or 
twice-daily, improves life expectancy and is cost-saving compared to IGlarg in the 
Chinese setting. 
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OBJECTIVES: Our objective was to compare the cost-effectiveness of glimepiride 
versus pioglitazone in combination with metformin in patients with type 2 diabetes. 
METHODS: The cost-effectiveness analysis (CEA) was performed by using Markov 
Cohort Process Mode with type 2 diabetic patients. Increases in life-years gained 
(LYG) and quality-adjusted life-years (QALYs) were measured as the main indicators 
of effectiveness. Direct medical cost includes drug cost, monitoring cost (medical-
supplies expense, total medicine-preparation cost, medical treatment cost, examination 
cost), and nursing cost (charged). Direct nonmedical cost includes the money spent 
on transportation by patients and families and indirect cost includes the time cost by 
patients and families. RESULTS: The Cost-Effectiveness Analysis (CEA) results 
showed that the combination therapy of metformin and glimepiride incurs total cost 
of KRW 5,652,814 to gain 8.065 LYG and 6.524 QALY. The combination therapy 
of metformin and pioglitazone costs KRW 8,613,622 to gain respective 8.836 LYG 
and 7.159 QALY. Thus the incremental cost-effectiveness ratios (ICERs) between two 
combination therapies were estimated to be KRW 3,837,632/LYG and KRW 
4,658,636/QALY. CONCLUSIONS: In terms of ICER values, KRW 3,837,632/LYG 
and KRW 4,658,636/QALY, there is no dominant alternative therefore the cost-
effective alternative between two alternatives will be able to be selected depending on 
threshold in willingness to pay or ICER of South Korea. 
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OBJECTIVES: Because of the rising prevalence of diabetes, the objective of this study 
was to better understand the population of patients who are at high risk for developing 
diabetes, but not yet diagnosed. Speciﬁ cally, this study examined the health outcomes 
between those at-risk for developing diabetes and controls. METHODS: This study 
utilized data from two large, cross-sectional, Internet-based survey databases, supple-
mented in China with centralized locations: the 2009 US and 2009 China National 
Health and Wellness Surveys (NHWS). Applying a previously-developed algorithm 
(Bang et al, 2009), patients in each country who were not diagnosed with diabetes 
were classiﬁ ed as having or not having a high risk for developing diabetes. High-risk 
patients were compared with controls on health-related quality of life (physical com-
ponent summary (PCS) scores of the SF-12v2) and the number of emergency room 
(ER) visits, controlling for demographics (country, age, gender, ethnicity, income, 
education) and patient characteristics (BMI and Charlson comorbidity index). 
RESULTS: Of those not diagnosed with diabetes, 2.46% of patients (n = 310) in China 
and 16.64% of patients (n = 10778) in the United States were classiﬁ ed as high risk 
for diabetes. After controlling for demographics and patient characteristics, those at 
high risk for diabetes reported signiﬁ cantly lower levels of PCS (Adjusted Mean [Madj] 
= 45.5 vs. 48.8, P < 0.0001). Although high-risk patients reported signiﬁ cantly more 
ER visits than controls in China (M = 0.44 vs. 0.40) they reported signiﬁ cantly less 
than controls in the United States (M = 0.12 vs. 0.17). These effects were signiﬁ cantly 
different between countries (χ2[1] = 5.25, P = 0.022). CONCLUSIONS: Although 
substantially more US patients were at high risk for developing diabetes relative to 
Chinese patients, the health outcome differences between those at high-risk and 
controls were more dramatic in China. Chinese patients at high-risk for diabetes 
reported signiﬁ cantly worse physical quality of life and more ER visits than 
controls. 
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OBJECTIVES: To assess the patient’s adherence to diabetic medications using 8-item 
Morisky medication adherence scale (MMAS) and to evaluate the association between 
patients’ adherence and the diabetic control outcome. METHODS: A convenience 
sample of 223 type 2 diabetic outpatients was identiﬁ ed between May and September, 
2009 from the Penang General Hospital, Penang, Malaysia. Patients who had taken 
oral antidiabetic medications with or without insulin were eligible for the research. 
Eight-item MMAS was used to assess medication adherence. Medical records were 
reviewed for Hemoglobin A1C (HbA1C) levels and other relevant clinical data. 
RESULTS: Based on the inclusion criteria, only 175 were included in the ﬁ nal analysis. 
Employing the recommended method of scoring, the mean ± SD of MMAS scores was 
6.13 ± 1.72 in which 38% were low, 44% were medium and only 17% were in high 
adherence group. Signiﬁ cant differences in educational levels, HbA1c levels, number 
of medications per day, MMAS scores among the three groups (P < 0.05). No signiﬁ -
cant differences have been found in age, sex, BMI, race, employment and diabetic 
duration among the three groups of adherence (P ≥ 0.05). MMAS scores correlates 
signiﬁ cantly with HbA1c (−0.431 P < 0.01). CONCLUSIONS: This study has shown 
that the short, easily administered 8-item MMAS is a useful tool for measuring medica-
tion adherence in diabetic patients. This study found that patients with lower score 
of MMAS had a higher HbA1c. The present study suggested that MMAS can be used 
for identifying type 2 diabetes patients with poor adherence to their medications. 
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OBJECTIVES: To assess health status, health-related quality of life (HRQoL), treat-
ment satisfaction (TS) and patient characteristics associated with these outcomes 
among Thai patients with diabetes. METHODS: Randomly selected patients with 
Type 2 diabetes aged ≥18 years were recruited from Samut Sakhon Hospital in Thai-
land from December 2008 to February 2009 in this cross-sectional study. The Thai 
versions of the EuroQol 5-Dimensions (EQ-5D) and the Audit of Diabetes-Dependent 
Quality of Life (ADDQoL-19) Questionnaire were used to assess health status and 
HRQoL, respectively, while the Diabetes Treatment Satisfaction Questionnaire status 
version (DTSQs) was used to assess satisfaction with diabetes treatment. RESULTS: 
A total of 201 patients were recruited with the majority being female, aged ≥45 years, 
of primary education and required only oral antidiabetes therapy. Their mean ± SD 
